Posted by Michael Wonder on 19 Jul 2022
Apellis announces FDA acceptance and priority review of the new drug application for pegcetacoplan for the treatment of geographic atrophy
19 July 2022 - PDUFA target action date is 26 November 2022.
Apellis Pharmaceuticals today announced that the U.S. FDA has accepted and granted priority review designation for the intravitreal pegcetacoplan new drug application.
